Another miss for Gilead, in a key market segment for ADC's.
"Trodelvy belongs to a class of widely sought-out treatments called antibody-drug conjugates, or ADCs, which deliver a cancer-killing therapy to specifically target and kill cancer cells and minimize damage to healthy ones. Standard chemotherapy is less selective — it can affect both cancer cells and healthy cells.
ADCs are one of the hottest areas of the pharmaceutical industry, as large drugmakers ink deals to acquire or co-develop them."